Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is a commercial-stage company creating a portfolio of targeted therapies to treat immune-mediated dermatological diseases and conditions. Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) Market Cap: $2.47B; Current Share Price: 20.57 USD Data by YCharts ZORYVE® - Time to Have Skin in This Game! The Company has...
Emergent BioSolutions, Inc. (NYSE: EBS), a life sciences company is developing a portfolio of vaccines and therapeutics for urgent health threats, announced the acceptance of a Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted) by the U.S. Food and Drug Administration (FDA). The...
Harmony Biosciences, Inc. (NASDAQ: HRMY) is a commercial-stage biopharmaceutical Company developing novel therapeutics for rare and orphan diseases, focusing on central nervous system disorders. Pitolisant, its lead product candidate, is a first-in-class histamine 3 (H3) receptor antagonist/inverse agonist that can help treat excessive daytime sleepiness...
Insider selling cannot be the sole indicator for investing in a stock, but it would be wise to make a note of the buying and selling activities to gauge a company’s prospects or the lack thereof. While insiders buying or selling the Company’s stock could...
DermTech Inc (NASDAQ: DMTK) is pioneering a new way for detecting skin cancer through a smart sticker, which eliminates the need for a biopsy and the use of a scalpel to collect skin samples for detection of melanoma. The technology promises to revolutionize the melanoma...
The Company is developing a pipeline of candidates focused on small molecules and biologics that can treat central nervous system (CNS) and immunology disorders. Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) lead candidate for CNS is TNX-102 SL (sublingual formulation of cyclobenzaprine), a non-opioid, centrally-acting analgesic...
Biotech Companies continue to show resurgence even in these challenging times, with more and more companies persevering with bringing their clinical candidates to fruition. While Vaccine development and therapeutics to combat the COVID-19 pandemic are at the forefront of development activities in the biotech sector,...
Covid-19 has bought many biotech companies into the limelight, all promising a possible solution to the pandemic that has disrupted lives worldwide. In February 2021, Ocugen, Inc. (NASDAQ: OCGN) shares catapulted after news of the Company signing a binding letter of intent (LOI) with Bharat...
T2 Biosystems, Inc. recently announced that its T2SARS-CoV-2™ Panel, a molecular diagnostic test that detects SARS-CoV-2, can detect the Brazil (P.1) variant of the SARS-CoV-2 virus. This expands the utility of its panel to reliably detect newer variants that have emerged in United Kingdom (B.1.1.7)...
Sesen Bio, Inc. (NASDAQ: SESN) is focused on creating targeted fusion protein therapeutics (TFPTs) for treatment of cancers. The Company is looking at a major catalyst in 2021, the approval of Vicineum, a potential best-in-class therapeutic for the treatment of non-muscle invasive bladder cancer (NMIBC)...
